[HTML][HTML] Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortality

…, D Conde, I Krsnik, E Prieto, R Riaza Grau… - Blood cancer …, 2020 - nature.com
There is limited information on the characteristics, prognostic factors, and outcomes of patients
with multiple myeloma (MM) hospitalized with COVID-19. This retrospective case series …

[HTML][HTML] Risk factors and mortality of COVID-19 in patients with lymphoma: a multicenter study

…, P Estival, K Quiroz-Cervantes, RR Grau… - …, 2021 - journals.lww.com
Patients with cancer are poorly represented in coronavirus disease 2019 (COVID-19) series,
and heterogeneous series concerning hematology patients have been published. This …

A prognostic model for survival after salvage treatment with FLAG‐Ida+/− gemtuzumab‐ozogamicine in adult patients with refractory/relapsed acute myeloid …

…, ML Amador‐Barciela, R RiazaGrau… - British Journal of …, 2016 - Wiley Online Library
The combination of fludarabine, cytarabine, idarubicin, and granulocyte colony‐stimulating
factor ( FLAG ‐Ida) is widely used in relapsed/refractory acute myeloid leukaemia ( AML ). We …

Acute myeloid leukemia with inv (3)(q21. 3q26. 2)/t (3; 3)(q21. 3; q26. 2): Study of 61 patients treated with intensive protocols

…, MB Vidriales, R RiazaGrau… - European Journal of …, 2020 - Wiley Online Library
Introduction Inv(3)(q21.3q26.2)/t(3;3)(q21.3;q26.2) is a rare poor prognosis cytogenetic
abnormality present in acute myeloid leukemia (AML) and other myeloid neoplasms. Objective …

[HTML][HTML] Worldwide examination of patients with CLL hospitalized for COVID-19

…, M Varettoni, M Marchetti, P Romero, RR Grau… - Blood, 2020 - Elsevier
Methods: This international collaboration represents a partnership between investigators at
141 centers. Data are presented in two cohorts. Cohort 1 (Co1) includes pts captured …

[HTML][HTML] No Evidence that CD33 rs12459419 Polymorphism Predicts Gemtuzumab Ozogamicin Response in Consolidation Treatment of Acute Myeloid Leukemia …

…, MJ Sayas-Lloris, MT Olave, R Riaza-Grau… - Disease …, 2022 - hindawi.com
Gemtuzumab ozogamicin (GO) is a conjugate of a monoclonal antibody and calicheamicin,
which has been reapproved for the treatment of acute myeloid leukemia (AML). AML patients …

[HTML][HTML] Impact of sars-Cov-2 infection in hematopoietic transplant patients: experience from the Madrid group

…, M Calbacho, A Chinea, P Llamas, RR Grau… - Blood, 2020 - Elsevier
Peter Paschka and Hartmut Döhner contributed equally. Background. SARS-CoV-2 infection
(COVID-19) has had a great impact worldwide and its mortality has been reported to be …

[HTML][HTML] Compresión medular por sarcoma granulocítico primario

…, JL Agud Aparicio, R Riaza Grau… - Revista Colombiana …, 2015 - scielo.org.co
El sarcoma granulocítico (SG) es una lesión poco frecuente asociada a síndromes
mielodisplásicos, mieloproliferativos o leucemias, aunque puede ser el primer hallazgo en un …

Real-World Outcomes Using Front-Line Midostaurine in Combination with Intensive Chemotherapy for Patients Aged≥ 60 Years Old with FLT3 Mutated Acute Myeloid …

…, M Tormo, M Carre, MJ Garcia, A Contejean, RR Grau… - Blood, 2023 - Elsevier
BACKGROUND: The prognosis of patients with acute myeloid leukemia (AML) varies depending
on the presence of mutations in the FLT3 tyrosine kinase. Internal tandem duplications (…

Spinal cord compression due to nonleukemic granulocytic sarcoma

…, JL Agud Aparicio, R Riaza Grau… - Revista Colombiana …, 2015 - scielo.org.co
Spinal cord compression due to nonleukemic granulocytic sarcoma SciELO - Scientific
Electronic Library Online vol.19 issue4 Circulating microRNAs as potential cancer …